

22 May 2008

ProStrakan Group plc (the "Company")

Annual information update for period 1 June 2007 up to and including 22 May 2008

This annual information update is required by and is being made pursuant to Article 10 of the Prospectus Directive as implemented in the United Kingdom (Prospectus Rule 5.2) and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained herein (except as expressly set out herein). The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Neither this annual information update, nor the information referred to below, constitutes by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.

1. Announcements made via RNS, a regulatory information service.

The following announcements were made by the Company via RNS, a regulatory information service, and may be viewed and downloaded from the London Stock Exchange website (www.londonstockexchange.com/marketnews).

<u>Date of publication</u>	<u>Brief description of announcement</u>
20-May-08	AGM Statement: Result of resolutions passed at Annual General Meeting
19-May-08	Re Agreement: ProStrakan announces Torrex Chiesi as partner for Xomolix in Austria and CEE
15-May-08	Interim Management Statement
08-May-08	Research Update: ProStrakan announces positive results from pivotal US "Fortify" study on Fortigel™ (testosterone 2% gel)
28-Apr-08	Annual Report and Accounts
23-Apr-08	Regulatory Update: FDA Moves Sancuso PDUFA Date to mid-June
02-Apr-08	Xomolix European Approvals: Xomolix Receives Additional Key European Approvals
25-Mar-08	Share Plans
13-Mar-08	Final Results: Preliminary results for the year ended 31 December 2007
07-Mar-08	Regulatory Approval: Rapinyl Receives Swedish Marketing Authorisation
18-Feb-08	Notice of Results: 2008 Financial Calendar Update
28-Jan-08	Directorate Change: Alan Walker
14-Jan-08	Director/PDMR Shareholding
08-Jan-08	Trading Update: ProStrakan Reports Further Strong Progress in Pre-Close Update
07-Jan-08	Director/PDMR Shareholding
17-Dec-07	Research Update: Positive US Phase III Interim Data on Rapinyl Released by Endo Pharmaceuticals Inc
12-Dec-07	Holding(s) in Company
07-Dec-07	Board Change: Harry Stratford
03-Dec-07	Regulatory Approval: ProStrakan Receives Approval for Adcal-D3 Dissolve
30-Nov-07	Blocklisting Interim Review

28-Nov-07	Price Monitoring Extension
28-Nov-07	Second Price Monitoring Extn
26-Nov-07	Notice of Results: 2008 Financial Calendar Update
31-Oct-07	Total Voting Rights
30-Oct-07	Board Change: Peter Allen
22-Oct-07	Re Alliance: ProStrakan to Establish US Sales Force through Strategic Alliance with NovaQuest
10-Oct-07	Additional Listing
28-Sep-07	Regulatory Update: Rapinyl EU approval process enters extended phase and Droperidol receives EU approval
27-Sep-07	Milestone payment: ProStrakan and Galapagos receive additional milestone payment in antibody collaboration
18-Sep-07	Holding(s) in Company
12-Sep-07	Interim Results: Interim Results for the Six Months Ended 30 June 2007
04-Sep-07	Notice of Results
20-Aug-07	Research Update: ProStrakan announces commencement of recruitment in pivotal US Trials for Fortigel (Tostran) and Cellegesic (Rectogesic)
13-Aug-07	Re Agreement: ProStrakan Announces LG Life Sciences as South Korean Partner for Sancuso®
01-Aug-07	Re Agreement: ProStrakan Launches Nordic Sales Joint Venture with Orexo
25-Jul-07	Re Agreement: Prostrakan and Galapagos receive milestone payment in antibody collaboration
16-Jul-07	Regulatory Application: ProStrakan Announces Filing of MAA for Sancuso®
06-Jul-07	Holding(s) in Company
05-Jul-07	Trading Statement: ProStrakan Reports Strong Revenue Growth in Pre-Close Trading Update
02-Jul-07	Total Voting Rights
26-Jun-07	Board Change: Simon Turton/Nicholas Lowcock
25-Jun-07	Result of AGM
15-Jun-07	Financial Calendar: 2007 Financial Calendar Update
13-Jun-07	Additional Listing
11-Jun-07	Product Launch: UK Launch of ProStrakan's Latest Pan EU Product – Tostran® (2% testosterone gel)
06-Jun-07	Annual Report and Accounts
01-Jun-07	Total Voting Rights
01-Jun-07	Annual Information Update

2. Documents filed at Companies House

The documents listed below were filed with the Registrar of Companies in Scotland on or around the dates indicated. Copies of these documents may be obtained from Companies House, 37 Castle Terrace, Edinburgh EH1 2EB, email: enquiries@companieshouse.gov.uk or www.companieshouse.gov.uk. If you are a registered user, they may be downloaded from the Companies House Direct website www.direct.companieshouse.gov.uk.

<u>Date of publication</u>	<u>Document</u>
08-Feb-08	Certificate of registration of charge: Novaquest - Pledge and Security Agreement dated 21 January 2008
06-Feb-08	Form 288b – Resignation of Alan Keith Iestyn Walker as director of the Company
12-Dec-07	Form 288b – Resignation of Harry Thomas Stratford as director of the Company
17-Oct-07	Form 88(2) – Return of allotment of ordinary 20,000 shares
29-Aug-07	Form 363s – Annual Return
25-Jul-07	Form 288b – Resignation of Adrian David Edmund Gardner as director of the Company
25-Jul-07	Form 288a – Appointment of Simon Turton as director of the Company
28-Jun-07	Form 288a – Appointment of Paul Maurice Garvey as director of the Company
28-Jun-07	Form 288b – Resignation of Nicholas John Lowcock as director of the Company
28-Jun-07	Annual Report and Accounts for the year ending 31 December 2006

3. Documents filed with the Financial Services Authority

The following documents have been filed by the Company with the Financial Services Authority. These documents may be viewed at the UK Listing Authority's Document Viewing Facility at 25 The North Colonnade, Canary Wharf, London E14 5HS and are available on the Company's website at www.prostrakan.com.

<u>Date of publication</u>	<u>Document</u>
20-May-08	Special Resolutions
28-Apr-08	Annual Report and Accounts 2007 and AGM Notice
30-Nov-07	Block listing six monthly return
05-Oct-07	Notification of application to the FSA and London Stock Exchange for additional listing following exercise of employee share options
07-Jun-07	Notification of application to the FSA and London Stock Exchange for additional listing following exercise of employee share options

Andrew McLean, Company Secretary
ProStrakan Group plc